AUTL Autolus Therapeutics
- 4.175
- +0.065+1.58%
Autolus Therapeutics News
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 0.35% to 1,403.4 on the S&P Europe Select ADR Index. From continental Europe, the gainers were le
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental E
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,
Abstract for Longer-term Follow-up and Additional Data Analysis of Pivotal Phase 2 FELIX Study of Obe-cel for Adult R/r B-ALL Selected for an Oral Presentation at ASCO
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
European equities traded in the US as American depositary receipts were treading water in Thursday morning session, nudging 0.006% higher to 1,330.06 on the S&P Europe Select ADR Index. From continent
Needham: Reiterated the Autolus Therapeutics (AUTL.US) rating, adjusted from buy to buy rating, target price of $9.00.
Needham: Reiterated the Autolus Therapeutics (AUTL.US) rating, adjusted from buy to buy rating, target price of $9.00.
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics with a Buy and maintains $9 price target.
GLYC, APLD and AUTL Are Among After Hour Movers
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
European equities traded in the US as American depositary receipts were weaker Thursday morning, falling 0.91% to 1,353.49 on the S&P Europe Select ADR Index.
Truist Securities: Maintains Autolus Therapeutics (AUTL.US) rating, adjusted from buy to buy rating, and adjusted target price from $10.00 to $11.00.
Truist Securities: Maintains Autolus Therapeutics (AUTL.US) rating, adjusted from buy to buy rating, and adjusted target price from $10.00 to $11.00.
Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $11
Truist Securities analyst Gil Blum maintains Autolus Therapeutics with a Buy and raises the price target from $10 to $11.
Autolus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 103.14% Truist Securities $10 → $11 Maintains Buy 03/18/2024 84.67% Truist Securities $9 → $10
Truist Raises Autolus Therapeutics Stock Target on Market Lead Potential
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European equities traded in the US as American depositary receipts opened the week in positive territory Monday morning, rising 0.50% to 1,380.48 on the S&P Europe Select ADR Index. From continental E
Autolus Therapeutics (NASDAQ:AUTL) Shareholders Are Still up 202% Over 1 Year Despite Pulling Back 12% in the Past Week
While Autolus Therapeutics plc (NASDAQ:AUTL) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 14% in the last quarter. On
Analysis
Price Target
No Data
